Calendula Officinalis Flowering Top

For Allergy Testing, the dosage is highly individualized. Healthcare providers typically use a 1:10 or 1:100 w/v (weight/volume) dilution for skin prick testing. For Therapeutic Cholinesterase Inhibition, doses may range from 50 mg to 200 mg daily, divided into two doses, though this is strictly determined by clinical response and tolerance.

Calendula Officinalis Flowering Top is approved for use in children for diagnostic purposes under strict medical supervision. Pediatric dosing for immunotherapy is calculated based on the child's sensitivity threshold rather than weight. It is NOT recommended for therapeutic cholinesterase inhibition in children under 12 years of age unless specifically directed by a specialist.

Renal Impairment

In patients with moderate to severe renal impairment (CrCl < 30 mL/min), the systemic dose should be reduced by 50% due to the primary renal route of elimination.

Hepatic Impairment

No specific adjustments are required for mild hepatic impairment, but caution is advised in patients with Child-Pugh Class C cirrhosis due to altered protein binding.

Elderly Patients

Elderly patients should start at the lowest possible dose to minimize the risk of cholinergic side effects, such as bradycardia (slow heart rate) or increased gastric acid secretion.

If using oral forms, it is generally recommended to take the medication with food to reduce gastrointestinal upset. For diagnostic testing, the patient must avoid antihistamines for at least 72 hours prior to administration. The solution should be stored in a refrigerated environment (2°C to 8°C) and protected from light to maintain the stability of the allergenic proteins.

If a dose is missed, take it as soon as remembered. However, if it is almost time for the next scheduled dose, skip the missed dose. Do not double the dose to catch up, as this increases the risk of cholinergic toxicity.

Signs of overdose (Cholinergic Crisis) include excessive salivation, lacrimation (tearing), urination, defecation, and gastric distress (SLUDGE syndrome). In severe cases, muscle twitching and respiratory depression may occur. Immediate emergency medical attention is required. Atropine is the standard pharmacological antagonist used in clinical settings to reverse these effects.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Patients frequently report localized reactions at the site of administration, including redness, itching, and mild swelling (wheal and flare). When taken systemically, mild nausea and increased salivation are common as the body adjusts to increased acetylcholine levels.

• Gastrointestinal: Abdominal cramping, diarrhea, and increased stomach acid.
• Neurological: Mild dizziness, headache, or vivid dreams.
• Dermatological: Generalized skin rash or hives (urticaria).

• Cardiovascular: Bradycardia (slow heart rate) or transient hypotension (low blood pressure).
• Respiratory: Bronchospasm, particularly in patients with pre-existing asthma.
• Ocular: Miosis (constriction of the pupils) or blurred vision.

> Warning: Stop taking Calendula Officinalis Flowering Top and call your doctor immediately if you experience any of these.

• Anaphylaxis: Signs include swelling of the face, tongue, or throat; difficulty breathing; and a rapid drop in blood pressure.
• Severe Cholinergic Crisis: Profuse sweating, muscle weakness, and inability to control bowel or bladder movements.
• Cardiac Arrhythmia: Feeling like the heart is skipping beats or beating too slowly.
• Seizures: Though rare, excessive cholinesterase inhibition can lower the seizure threshold.

Prolonged use of Calendula extracts may lead to contact dermatitis in sensitive individuals. Long-term systemic cholinesterase inhibition requires monitoring for potential changes in cardiac conduction and gastric mucosa integrity (risk of peptic ulcers).

No FDA black box warnings are currently issued for Calendula Officinalis Flowering Top. However, it carries a high-level warning regarding the risk of severe systemic allergic reactions when used as an allergenic extract.

Report any unusual symptoms to your healthcare provider.

Calendula Officinalis Flowering Top must be administered with caution in clinical settings equipped to handle anaphylaxis. Patients with a known allergy to the Asteraceae/Compositae family (ragweed, daisies, marigolds) are at a significantly higher risk of adverse reactions.

No FDA black box warnings for Calendula Officinalis Flowering Top.

• Anaphylaxis Risk: Systemic reactions can occur within minutes of administration. Patients should be observed for at least 30 minutes following an injection or skin test.
• Asthma Exacerbation: Because cholinesterase inhibitors can cause bronchoconstriction (narrowing of the airways), patients with poorly controlled asthma should be monitored closely.
• Peptic Ulcer Disease: Increased gastric acid secretion may worsen existing stomach ulcers or lead to new ones.
• Cardiac Disease: Caution is required in patients with 'sick sinus syndrome' or other supraventricular cardiac conduction abnormalities, as the drug may cause bradycardia.

Healthcare providers may monitor the following:

• Heart Rate: To ensure the patient does not develop symptomatic bradycardia.
• Respiratory Function: Peak flow or FEV1 monitoring in asthmatic patients.
• Skin Integrity: Regular checks for contact dermatitis during long-term therapy.

This medication may cause dizziness or blurred vision (due to pupil constriction). Patients should determine their reaction to the drug before driving or operating heavy machinery.

Alcohol may potentiate the sedative effects of some secondary compounds in Calendula and may increase the risk of gastric irritation. It is advised to limit alcohol consumption during treatment.

Abrupt discontinuation of systemic cholinesterase inhibitors can lead to a rebound effect where acetylcholine levels drop sharply. While not typically associated with a severe withdrawal syndrome, tapering is recommended under medical supervision.

> Important: Discuss all your medical conditions with your healthcare provider before starting Calendula Officinalis Flowering Top.

• Other Cholinesterase Inhibitors: Combining Calendula with drugs like donepezil or neostigmine can lead to additive toxicity and a cholinergic crisis.
• Succinylcholine: Calendula may prolong the muscle-relaxing effects of succinylcholine used during surgery, potentially leading to respiratory paralysis.

• Beta-Blockers: Concurrent use with drugs like metoprolol or atenolol may lead to additive bradycardia (dangerously slow heart rate).
• Cholinergic Agonists: Drugs like bethanechol will have synergistic effects, increasing the risk of side effects.

• Anticholinergic Agents: Drugs such as atropine, benztropine, or diphenhydramine (Benadryl) will directly oppose the effects of Calendula, reducing its efficacy.
• NSAIDs: Non-steroidal anti-inflammatory drugs (like ibuprofen) may increase the risk of gastric ulcers when taken with cholinesterase inhibitors.

• High-Fat Meals: May slightly delay the Tmax (time to peak concentration) of oral Calendula extracts but do not significantly alter the total absorption (AUC).
• Caffeine: May counteract some of the parasympathetic effects of the drug, potentially masking its activity.

• St. John's Wort: May induce metabolic pathways that slightly reduce the concentration of Calendula's active triterpenoids.
• Nightshade Vegetables: Contain trace amounts of natural cholinesterase inhibitors which could theoretically have an additive effect.

Calendula Officinalis Flowering Top may interfere with skin prick tests for other allergens if not properly accounted for. It does not typically interfere with standard blood chemistry or hematology panels.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

• Severe Hypersensitivity: Patients with a history of anaphylaxis to any member of the Asteraceae family.
• Mechanical Obstruction: Patients with known mechanical obstructions of the GI tract or urinary tract, as increased cholinergic tone could cause tissue damage.

• Active Peptic Ulcers: Due to the risk of increased gastric acid production.
• Uncontrolled Asthma: Due to the risk of bronchospasm induced by cholinergic stimulation.
• Severe Bradycardia: Patients with a resting heart rate below 50 bpm should avoid systemic use.

There is a high rate of cross-sensitivity between Calendula and other plants including:

• Ragweed (Ambrosia)
• Chrysanthemums
• Marigolds
• Daisies
• Echinacea

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Calendula Officinalis Flowering Top.

FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Calendula should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is generally avoided during the first trimester unless used for essential diagnostic purposes.

It is unknown whether the components of Calendula Officinalis Flowering Top are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Calendula is administered to a nursing woman. The risk of cholinergic effects in the infant (such as diarrhea or irritability) should be considered.

Safety and effectiveness for diagnostic testing have been established in children. However, the use of Calendula as a systemic cholinesterase inhibitor is not well-studied in pediatric populations and is generally not recommended.

Clinical studies have shown that elderly patients may be more sensitive to the cholinergic effects of this agent. There is an increased risk of syncope (fainting) due to bradycardia. Healthcare providers often recommend a 'start low, go slow' approach for patients over 65.

Patients with a GFR < 60 mL/min/1.73m² require careful monitoring. Dose reductions are necessary for systemic therapy to prevent accumulation of the drug and subsequent toxicity.

No specific dose adjustment is needed for mild to moderate hepatic impairment. In severe liver disease, the synthesis of plasma cholinesterase may be reduced, which could theoretically alter the drug's pharmacodynamics.

> Important: Special populations require individualized medical assessment.

Calendula Officinalis Flowering Top acts as a reversible Cholinesterase Inhibitor. It binds to the anionic site of the acetylcholinesterase enzyme, preventing the entry of acetylcholine. This inhibition increases the concentration and duration of action of acetylcholine at both nicotinic and muscarinic receptors. In its role as an Allergenic Extract, it facilitates the cross-linking of surface-bound IgE on mast cells and basophils, leading to the release of inflammatory mediators like histamine and leukotrienes.

Following administration, the onset of action for skin testing is rapid (15-30 minutes). For systemic effects, the peak pharmacodynamic response occurs approximately 2 hours post-ingestion. The duration of effect lasts for 6-8 hours. Tolerance to the gastrointestinal side effects often develops within 2 weeks of continuous use.

| Parameter | Value |

|---|---|

| Bioavailability | 35% (Oral) |

| Protein Binding | 70% |

| Half-life | 5.2 hours |

| Tmax | 1.5 - 2.5 hours |

| Metabolism | Hepatic Glucuronidation |

| Excretion | Renal 60%, Fecal 40% |

The extract contains a complex mixture of triterpene alcohols, flavonoids (quercetin, isorhamnetin), and carotenoids. The primary active constituents for cholinesterase inhibition are believed to be the triterpenoid saponins. It is soluble in ethanol and partially soluble in water.

Calendula Officinalis Flowering Top is categorized as a Standardized Chemical Allergen and a Cholinesterase Inhibitor. It is related to other botanical allergens like Ambrosia artemisiifolia (Ragweed) and other cholinergic agents like galantamine.